ResMed to Announce Fourth Quarter Fiscal Year 2017 Results

SAN DIEGO, June 29, 2017 /PRNewswire/ -- ResMed (NYSE: RMD) today announced it will report its fourth quarter of fiscal year 2017 results on Tuesday, August 1, 2017, after the New York Stock Exchange market closes. A press release with ResMed's results will be issued after 1:00 p.m. US Pacific Time and the company will host a webcast to discuss operating results and future outlook.

The earnings webcast is scheduled to begin at 1:30 p.m. US Pacific Time and the live webcast of the call can be accessed on ResMed's Investor Relations website at Please go to this section of the website and click on the icon for the "Q4 2017 earnings webcast."

Please note that we do not use outside phone lines to access the earnings call.

International earnings webcast times will be:

Tuesday, August 1, 9:30 p.m.


Wednesday, August 2, 6:30 a.m.


A replay of the earnings webcast will be accessible on our website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from August 1, 2017, until August 15, 2017, at:


+1 800-585-8367

Outside US:

+1 416-621-4642



About ResMed

ResMed (NYSE: RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries. ResMed.comFacebookTwitter | LinkedIn.

For media

For investors

Alison Graves

Agnes Lee

+1 858-836-6789

+1 858-836-5971


ResMed Inc. logo. (PRNewsFoto/ResMed Inc.)


To view the original version on PR Newswire, visit:

SOURCE ResMed Inc.